
|Slideshows|November 10, 2017
FDA Cancer Drug Approvals in 2017
Author(s)Cancer Network Editors
This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but by tumor marker.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC
3
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC
4
IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer
5





















































